Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?

BACKGROUND: Mesenchymal stem cell (MSC)-based therapies have yielded beneficial effects in a broad range of preclinical models and clinical trials for human diseases. In the context of MSC transplantation, it is widely recognized that the main mechanism for the regenerative potential of MSCs is not their differentiation, with in vivo data revealing transient and low engraftment rates. Instead, MSCs therapeutic effects are mainly attributed to its secretome, i.e., paracrine factors secreted by these cells, further offering a more attractive and innovative approach due to the effectiveness and safety of a cell-free product. AIM OF REVIEW: In this review, we will discuss the potential benefits of MSC-derived…

• EC
  European Commission
• FP
  Fundação para a Ciência e a Tecnologia

  Awards: HORIZON-HLTH-2022-STAYHLTH-02, UIDB/04138, 101095679, 539 SFRH/BD/09328/2021, SFRH/BD/09328/2021, UIDB/04138/2020, SFRH/BD/144130/2019, 540 UIDP/04138/2020, UIDP/04138/2020